Patient Voice Must Shape Rare Disease Development Before Decisions Are Made

October 16, 2026

At a public meeting hosted by the FDA and Reagan-Udall Foundation for the FDA (RUF) on October 16, patient advocates called on regulators, industry leaders, and rare disease treatment developers to involve patients before clinical trial protocols, endpoints, and product strategies are set.

Tagline Strategies attended the meeting, which focused on how patient perspectives are gathered across the treatment development timeline and how patient input can influence clinical trial design, evidence generation, benefit-risk decisions, and post-approval support.

The strongest discussion came during a panel on advancing the patient voice in treatment development. Speakers moved beyond the question of whether companies should engage patients at all, and focused on how to make that engagement useful, credible, and connected to decisions.

“Just bring them to the table and ask the questions,” said Dr. Allyson Berent, Chief Science Officer at the Foundation for Angelman Syndrome Therapeutics.

Berent was speaking to a recurring problem in rare disease development: teams may rely on established clinical assumptions or evidence of pharmacodynamic change without asking patients and caregivers what outcomes matter in daily life. Patient input can challenge those assumptions, identify burdens that a trial team may miss, and help companies assess whether an endpoint reflects a meaningful change.

Dr. Michelle Campbell, Associate Director for Stakeholder Engagement and Clinical Outcomes in the Office of New Drugs at the FDA, described the growth of patient engagement across the agency.

“It’s not grassroots anymore. It is systematic, it is scientific, and it is rigorous,” Dr. Campbell said.

That shift has implications for sponsors. Patient engagement is no longer limited to public listening sessions or advocacy outreach. It is becoming part of how companies and regulators think about evidence, endpoint selection, trial feasibility, and the interpretation of benefit and risk.

For biopharmaceutical companies, that expectation creates a practical obligation. Engagement plans should identify what decisions patient input will inform, how the information will be analyzed, and when participants will receive an explanation of what changed. When input cannot be adopted, companies should explain why.

Tom Croce, Vice President of Global Patient Advocacy and Engagement at Jazz Pharmaceuticals, framed the issue as a question of how medicines are developed.

“How are we developing medicines with patients, not for them? How are they part of our process?” Croce asked.

That distinction is important in rare disease, where patient organizations and families may hold deep knowledge of disease progression, treatment burden, care delivery, and unmet need. Their expertise can affect more than clinical trial recruitment. It can influence study design, visit schedules, outcome measures, patient-facing materials, and the services that accompany a product after approval.

Ashley Valentine, Co-founder and CEO of Sick Cells, put the value of that expertise in direct terms.

“The patient is the ultimate KOL,” she said.

The comment reflected a broader point made throughout the panel: patients are not simply sources of testimony. They are subject-matter experts with knowledge that can improve a development program. That expertise should be recognized through meaningful roles in treatment development, appropriate compensation, and access to the same level of respect given to clinical and scientific advisers.

The panel also addressed variation within rare disease communities. A single disease may affect people at different stages of progression, with different symptoms, treatment histories, caregiver responsibilities, and risk tolerance. A development strategy that captures only one part of that community may produce evidence that is incomplete or difficult to interpret.

For Tagline Strategies, the meeting reinforced five practical observations:

  • Patient engagement should begin before key decisions are fixed.
  • Patient experience should be translated into usable evidence.
  • Companies need a clear feedback loop.
  • Engagement plans should account for differences within a community.
  • And patient organizations should be treated as expert partners rather than informal sources of access or recruitment.

Tagline helps life sciences companies, patient organizations, and advocates bring patient insight, regulatory strategy, stakeholder engagement, and communications together. The goal is to make patient voices part of the work from the beginning, when it can most improve the decisions that shape a product and the people it is intended to serve.

Back to All News
Scenes from the Reagan-Udall Foundation’s Patient Voice event, bringing together patients, advocates, and stakeholders to discuss the role of patient perspectives in healthcare. (FDA photos)

Stay in the Know with
Our Latest Insights

Sign up for Tagline’s Newsletter, a digest of regulatory, policy, and communications developments shaping the industries we serve. We promise not to spam you! Our aim is to publish a quarterly newsletter with special features once in a while.

Sign Up